Publication date: Sep 11, 2019
OWOSSO, Mich. , Sept. 10, 2019 /PRNewswire/ — The Memorial Healthcare Institute for Neurosciences and Multiple Sclerosis, and its Chief of Neurology, Rany Aburashed, D. O., are the first in the U. S. to use Neurofilament Light Chain testing prospectively for patients with multiple sclerosis.
The impact of NfL for patients with Multiple Sclerosis Neurofilament light chain is a polypeptide that provides the structural framework and support to nerve cells.
As the first U. S. hospital to actively research NfL testing in real world patients with multiple sclerosis, Memorial Healthcare is paving the way for future treatment of MS. “A patient’s presentation, degree of disability and symptoms all make up a unique fingerprint to their disease,” said Dr. Aburashed.
“My primary goal here at Memorial is to create an environment that is conducive and attractive for health care providers to practice their trade at the highest level, and an environment where openness and collaboration exists,” said Brian Long, FACHE, president and CEO of Memorial Healthcare.
In addition to its investment in the NfL technology, Memorial Healthcare is investing nearly $30 million in a new facility that will specialize in neurology and orthopedics and will also house a health and wellness center for the community.
For more information about Memorial Healthcare, its Institute for Neurosciences and Multiple Sclerosis or the neurofilament light chain (NfL) research study, visit or call 989-723-1390.
- Roche to present pivotal data for satralizumab in neuromyelitis optica spectrum disorder and six-year OCREVUS data in multiple sclerosis at ECTRIMS
- Genentech Presents New Ocrevus (Ocrelizumab) Biomarker Data That Increase Understanding of Disease Progression in Multiple Sclerosis at ECTRIMS